Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression

Wang, Feng; Zu, Yanwen; Zhu, Shibin; Yu, Yang; Huang, Weijian; Xie, Hui; Li, Gonghui

doi:10.1016/j.bbrc.2018.11.013

Cited by 60 publications

(62 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genomewide transcriptome analysis showed that the development of IDD is characterized by an altered expression pattern of a large set of lncRNAs [15], indicating the involvement of lncRNAs in these diseases [16]. MAGI2-AS3 is a recently identified lncRNA with tumor suppression functions in breast cancer and bladder cancer [12,17]. In the present study, we showed that plasma circulating MAGI2-AS3 was significantly down-regulated in IDD patients, and down-regulation of MAGI2-AS3 effectively distinguished IDD patient from healthy people.…”

Section: Discussionmentioning

confidence: 99%

LncRNA MAGI2-AS3 is down-regulated in intervertebral disc degeneration and participates in the regulation of FasL expression in nucleus pulposus cells

Cui

Liu

Tang

et al. 2020

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background: It is known that Fas ligand (FasL) is involved in the development of intervertebral disc degeneration (IDD). A recent study reported that lncRNA MAGI2-AS3 up-regulated the expression of FasL to promote breast cancer. Therefore, we investigated the roles that lncRNA MAGI2-AS3 might play in IDD.Methods: A total of 66 IDD patients (IDD group) and 58 healthy volunteers (Control group) were recruited in this study. Quantitative real-time PCR (qRT-PCR) and western blot were used to investigate gene expression levels. Cell transfections were carried out to analyze gene interactions. The diagnostic value of lncRNA MAGI2-AS3 for IDD was assessed by ROC curve analysis. Results: The expression levels of plasma lncRNA MAGI2-AS3 were lower in IDD patients compared to that in the control group. Down-regulation of lncRNA MAGI2-AS3 effectively distinguished IDD patients from the control group. The expression levels of plasma lncRNA MAGI2-AS3 were significantly increased after the treatments. Over-expression of lncRNA MAGI2-AS3 inhibited the expression of FasL, while the silencing of lncRNA MAGI2-AS3 promoted the expression of FasL in nucleus pulposus (NP) cells.Conclusions: Therefore, lncRNA MAGI2-AS3 is down-regulated in IDD and participates in the regulation of FasL expression in nucleus pulposus (NP) cells.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA MAGI2-AS3 is down-regulated in intervertebral disc degeneration and participates in the regulation of FasL expression in nucleus pulposus cells

Cui

Liu

Tang

et al. 2020

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…The first report showing experimental evidence of MAGI2-AS3 playing a tumor-suppressive role in breast cancer by regulating the Fas/FasL was published in 2018 [28]. Soon thereafter, other reports [31,33,48] demonstrated the tumor-suppressive function of MAGI2-AS3 in bladder cancer hepatocellular cancer and gliomas. Therefore, one of the first aims of this study was to understand if the onco-suppressive role of MAGI2-AS3 extends to EOC, specifically HGSC originating from FT.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, several reports have been published [30][31][32][33] showing lncRNA MAGI2-AS3 as a microRNA (miRNA) sponge to carry out its tumor-suppressive role in breast cancer, bladder cancer, hepatocellular cancer, and non-small cell lung cancer. Investigating along these lines, MAGI2-AS3 has been experimentally demonstrated to regulate the expression of three miRNAs-miR-15b-5p, miR-374a-5p, and miR-374b-5p that were previously associated with this lncRNA in other cancers [31][32][33]. It is indeed interesting to note that these three miRNAs that are upregulated in EOC [36] have been reported to have oncogenic roles in several other cancers [38,40,41,[49][50][51][52][53][54][55][56][57][58].…”

Section: Discussionmentioning

confidence: 99%

“…LncRNAs are commonly reported to have competing endogenous RNA function by sponging miRNAs in cytoplasm [16]. To identify MAGI2-AS3 miRNA targets in EOC, using Starbasev3.0 [29] and literature survey [30][31][32][33], a list of demonstrated and predicted miRNA targets was obtained. This was then matched with a list of all the differentially expressed miRNAs between EOC and FT [34,35].…”

Section: Magi2-as3 Acts As a Competing Endogenous Lncrna In Hgsc And mentioning

confidence: 99%

“…Figure 5a shows a comparison of these two lists represented as a Venn diagram, and the common miRNAs obtained from both these lists are represented in Figure 5b. Three miRNAs-miR-15b-5p, miR-374a-5p, and miR-374b-5p [30][31][32][33], highlighted in bold, were previously reported to be sponged by MAGI2-AS3 in other cancers, as shown in Supplementary Materials Table S3.…”

Section: Magi2-as3 Acts As a Competing Endogenous Lncrna In Hgsc And mentioning

confidence: 99%

See 2 more Smart Citations

Long Non-Coding RNA MAGI2-AS3 is a New Player with a Tumor Suppressive Role in High Grade Serous Ovarian Carcinoma

Gokulnath

Cristofaro

Manipur

et al. 2019

Cancers

View full text Add to dashboard Cite

High-Grade Serous Ovarian Carcinoma (HGSC) is the most incidental and lethal subtype of epithelial ovarian cancer (EOC) with a high mortality rate of nearly 65%. Recent findings aimed at understanding the pathogenesis of HGSC have attributed its principal source as the Fallopian Tube (FT). To further comprehend the exact mechanism of carcinogenesis, which is still less known, we performed a transcriptome analysis comparing FT and HGSC. Our study aims at exploring new players involved in the development of HGSC from FT, along with their signaling network, and we chose to focus on non-coding RNAs. Non-coding RNAs (ncRNAs) are increasingly observed to be the major regulators of several cellular processes and could have key functions as biological markers, as well as even a therapeutic approach. The most physiologically relevant and significantly dysregulated non-coding RNAs were identified bioinformatically. After analyzing the trend in HGSC and other cancers, MAGI2-AS3 was observed to be an important player in EOC. We assessed its tumor-suppressive role in EOC by means of various assays. Further, we mapped its signaling pathway using its role as a miRNA sponge to predict the miRNAs binding to MAGI2AS3 and showed it experimentally. We conclude that MAGI2-AS3 acts as a tumor suppressor in EOC, specifically in HGSC by sponging miR-15-5p, miR-374a-5p and miR-374b-5p, and altering downstream signaling of certain mRNAs through a ceRNA network.

show abstract

Long noncoding RNA MAGI2‐AS3/miR‐218‐5p/GDPD5/SEC61A1 axis drives cellular proliferation and migration and confers cisplatin resistance in nasopharyngeal carcinoma

Cao

Zhou

2020

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background: Nasopharyngeal carcinoma (NPC), a subclass of neck and head cancers, is the predominant cause of cancer-associated death globally. LncRNA MAGI2-AS3 has been previously reported to be associated with multiple cancers, but its molecular mechanism in NPC has not been fully explained. Hence, the purpose of this study is to identify the role and regulatory mechanism of MAGI2-AS3 in NPC. Methods: Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot (WB) were employed to examine gene levels. The biologic function of MAGI2-AS3 in NPC was estimated by cell counting, EdU, Transwell, and WB assays. Luciferase reporter and radioimmunoprecipitation (RIP) assays were carried out to determine the combination between miR-218-5p and MAGI2-AS3, GDPD5, and SEC61A1. Results: MAGI2-AS3 is expressed at a high level in NPC cell lines. Moreover, MAGI2-AS3 knockdown-suppressed NPC progression in vitro and in vivo. Furthermore, MAGI2-AS3 functioned as a competing endogenous RNA (ceRNA) by sponging miR-218-5p to increase the expression of GDPD5 in NPC. Importantly, it was found that MAGI2-AS3 regulated NPC progression and cisplatin resistance via modulating GDPD5. In addition, MAGI2-AS3 could also promote the proliferation and migration in NPC cells by regulating SEC61A1. Conclusion: MAGI2-AS3/miR-218-5p/GDPD5/SEC61A1 axis drove cell proliferation, migration, and epithelialmesenchymal transition, and conferred cisplatin resistance in NPC, which may provide a novel insight into the development of NPC.

show abstract

Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression

Cited by 60 publications

References 26 publications

LncRNA MAGI2-AS3 is down-regulated in intervertebral disc degeneration and participates in the regulation of FasL expression in nucleus pulposus cells

LncRNA MAGI2-AS3 is down-regulated in intervertebral disc degeneration and participates in the regulation of FasL expression in nucleus pulposus cells

Long Non-Coding RNA MAGI2-AS3 is a New Player with a Tumor Suppressive Role in High Grade Serous Ovarian Carcinoma

Long noncoding RNA MAGI2‐AS3/miR‐218‐5p/GDPD5/SEC61A1 axis drives cellular proliferation and migration and confers cisplatin resistance in nasopharyngeal carcinoma

Contact Info

Product

Resources

About